HK1174539A1 - Met inhibitors for enhancing radiotherapy efficacy met - Google Patents

Met inhibitors for enhancing radiotherapy efficacy met

Info

Publication number
HK1174539A1
HK1174539A1 HK13101476.6A HK13101476A HK1174539A1 HK 1174539 A1 HK1174539 A1 HK 1174539A1 HK 13101476 A HK13101476 A HK 13101476A HK 1174539 A1 HK1174539 A1 HK 1174539A1
Authority
HK
Hong Kong
Prior art keywords
met
inhibitors
enhancing radiotherapy
radiotherapy efficacy
efficacy
Prior art date
Application number
HK13101476.6A
Other languages
English (en)
Chinese (zh)
Inventor
Paolo Maria Comoglio
Carla Boccaccio
Fiorella Petronzelli
Rita De Santis
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Publication of HK1174539A1 publication Critical patent/HK1174539A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK13101476.6A 2011-03-18 2013-02-01 Met inhibitors for enhancing radiotherapy efficacy met HK1174539A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158861.2A EP2500036B1 (en) 2011-03-18 2011-03-18 MET inhibitors for enhancing radiotherapy efficacy

Publications (1)

Publication Number Publication Date
HK1174539A1 true HK1174539A1 (en) 2013-06-14

Family

ID=44260211

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13101476.6A HK1174539A1 (en) 2011-03-18 2013-02-01 Met inhibitors for enhancing radiotherapy efficacy met

Country Status (23)

Country Link
US (1) US20120237524A1 (sl)
EP (1) EP2500036B1 (sl)
JP (1) JP5671487B2 (sl)
KR (1) KR101540838B1 (sl)
CN (1) CN102688491A (sl)
AU (1) AU2012201303B2 (sl)
BR (1) BR102012006063B1 (sl)
CA (1) CA2769991C (sl)
CY (1) CY1115374T1 (sl)
DK (1) DK2500036T3 (sl)
EA (1) EA028590B1 (sl)
ES (1) ES2489475T3 (sl)
HK (1) HK1174539A1 (sl)
HR (1) HRP20140729T1 (sl)
IL (1) IL218293A (sl)
MX (1) MX2012003084A (sl)
PL (1) PL2500036T3 (sl)
PT (1) PT2500036E (sl)
RS (1) RS53468B (sl)
SG (1) SG184637A1 (sl)
SI (1) SI2500036T1 (sl)
SM (1) SMT201400106B (sl)
ZA (1) ZA201201992B (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN110320365B (zh) * 2019-07-06 2022-07-22 湖南莱拓福生物科技有限公司 NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
BRPI0412885A (pt) * 2003-07-18 2006-10-03 Amgen Inc polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimento hepatócito (hgf)
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
ATE514715T1 (de) * 2006-02-06 2011-07-15 Metheresis Translational Res Sa Monoklonaler anti-met-antikörper, fragmente und vektoren davon zur behandlung von tumoren und entsprechende produkte
EP2019116A1 (en) * 2007-07-26 2009-01-28 Helmholtz-Zentrum für Infektionsforschung GmbH Inhibitor of the met-receptor and its use

Also Published As

Publication number Publication date
BR102012006063A8 (pt) 2022-11-08
JP2012196206A (ja) 2012-10-18
EA201200329A3 (ru) 2013-01-30
CA2769991A1 (en) 2012-09-18
EP2500036A1 (en) 2012-09-19
JP5671487B2 (ja) 2015-02-18
MX2012003084A (es) 2012-09-17
KR20120106582A (ko) 2012-09-26
AU2012201303A1 (en) 2012-10-04
CN102688491A (zh) 2012-09-26
EA201200329A2 (ru) 2012-09-28
SG184637A1 (en) 2012-10-30
AU2012201303B2 (en) 2013-11-07
EA028590B1 (ru) 2017-12-29
US20120237524A1 (en) 2012-09-20
IL218293A0 (en) 2012-07-31
ZA201201992B (en) 2015-05-27
PL2500036T3 (pl) 2014-10-31
DK2500036T3 (da) 2014-08-04
SMT201400106B (it) 2014-11-10
ES2489475T3 (es) 2014-09-02
CA2769991C (en) 2018-05-15
BR102012006063A2 (pt) 2021-11-16
HRP20140729T1 (hr) 2014-08-29
EP2500036B1 (en) 2014-05-07
SI2500036T1 (sl) 2014-09-30
IL218293A (en) 2016-06-30
KR101540838B1 (ko) 2015-08-06
CY1115374T1 (el) 2017-01-04
BR102012006063B1 (pt) 2023-03-07
RS53468B (en) 2014-12-31
PT2500036E (pt) 2014-08-25

Similar Documents

Publication Publication Date Title
HK1257823A1 (zh) 金屬酶抑制劑化合物
HK1198163A1 (en) Metalloenzyme inhibitor compounds
HK1198651A1 (en) Metalloenzyme inhibitor compounds
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2723731A4 (en) COMPOUNDS INHIBITING METALLOENZYMES
HUE060305T2 (hu) FAP-aktivált proteaszóma inhibitorok a szolid tumorok kezelésére
EP2776126A4 (en) DEFINITION OF EFFECTIVE DEFIBRILLATION
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
HK1200840A1 (en) Dpp-4 inhibitor dpp-4
HK1174539A1 (en) Met inhibitors for enhancing radiotherapy efficacy met
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2694057A4 (en) LIPOXYGENASE INHIBITORS
EP2768512A4 (en) ENZYME HAMMER FOR CANCER TREATMENT
ZA201306074B (en) Cathepsin c inhibitors
GB201120474D0 (en) Inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
IL225526A0 (en) Matrix metalloproteinase inhibitors
IL225528A0 (en) Matrix metalloproteinase inhibitors
IL225527A0 (en) Matrix metalloproteinase inhibitors
GB201104399D0 (en) Novel inhibitors